38330-80-2

Basic information

• Product Name: Potassium 3-methoxy-3-oxopropanoate
• Synonyms: POTASSIUM MONOMETHYL MALONATE;POTASSIUM METHYL MALONATE;POTASSIUM 3-METHOXY-3-OXOPROPANOATE;MONO-METHYL MALONATE POTASSIUM SALT;MONOMETHYL MONOPOTASSIUM MALONATE;MALONIC ACID MONOMETHYL ESTER POTASSIUM;KMM;METHYL MONO POTASSIUM MALONATE
• CAS NO: 38330-80-2
• Molecular Formula: C₄H₅O₄*K
• Molecular Weight: 156.18
• EINECS: 253-886-8
• Product Categories: Miscellaneous Reagents;Aliphatics;Inhibitors
• Mol File: 38330-80-2.mol

Chemical Properties

• Melting Point: 200 °C
• Boiling Point: 232.1 °C at 760 mmHg
• Flash Point: 103.7 °C
• Appearance: White/Crystalline Powder
• Vapor Pressure: 0.0211mmHg at 25°C
• Storage Temp.: Refrigerator
• Solubility: Soluble in methanol.
• BRN: 3633585
• CAS DataBase Reference: Potassium 3-methoxy-3-oxopropanoate(CAS DataBase Reference)
• NIST Chemistry Reference: Potassium 3-methoxy-3-oxopropanoate(38330-80-2)
• EPA Substance Registry System: Potassium 3-methoxy-3-oxopropanoate(38330-80-2)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 37/39-26
• WGK Germany: 3
• F: 3
• Hazardous Substances Data: 38330-80-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Potassium 3-methoxy-3-oxopropanoate is used as a protein advanced glycosylation inhibitor for managing and treating conditions related to protein glycosylation, which can lead to several health issues.
Used in Chemical Synthesis:
In the field of organic chemistry, Potassium 3-methoxy-3-oxopropanoate is utilized in the total synthesis of (±)-vincorine, an akuammiline alkaloid with potential applications in biology. Additionally, it can be used to synthesize a key keto proline ester intermediate, which is essential for preparing acutumine.
These applications highlight the importance of Potassium 3-methoxy-3-oxopropanoate in both the pharmaceutical and chemical synthesis industries, showcasing its versatility and potential for further research and development.

InChI:InChI=1/C4H6O4/c1-8-4(7)2-3(5)6/h2H2,1H3,(H,5,6)/p-1

Upstream product

• 108-59-8 malonic acid dimethyl ester 
• 67-56-1 methanol 
• 105-53-3 diethyl malonate 

Downstream Products

• 22984-61-8 methyl 2-oxo-5-phenyltetrahydrofuran-3-carboxylate 
• 121587-95-9 dihydro-5-(2,5-dimethoxyphenyl)-3,4-di(carboxymethyl)-2(3H)-furanone 
• 134302-93-5 4-ethyl 3-methyl rel-(3R,4S,5S)-2-oxo-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran-3,4-dicarboxylate 
• 121587-91-5 dihydro-5-(4-methoxyphenyl)-3,4-di(carboxymethyl)-2(3H)-furanone 
• 121587-94-8 (3α, 4β, 5α)-dihydro-5(3,4-dimethoxyphenyl)-3,4-di(carboxymethyl)-2(3H)-furanone 
• 117856-16-3 dihydro-5-(3,4,5-trimethoxyphenyl)-3,4-di(carboxymethyl)-2(3H)-furanone 
• 121587-97-1 (3α, 4β, 5α)-dihydro-5-(2,4,5-trimethoxyphenyl)-3,4-di(carboxymethyl)-2(3H)-furanone 
• 122483-69-6 (3α, 4β, 5α)-dihydro-5-(2,3,4-trimethoxyphenyl)-3,4-di(carboxymethyl)-2-(3H)-furanone 
• 65985-76-4 methyl (S)-4-(((benzyloxy)carbonyl)amino)-3-oxo-5-phenylpentanoate 
• 129081-64-7 methyl 5-(4-hydroxyphenyl)-4-N-(benzyloxycarbonyl)amino-3-oxopentanoate 
• 129081-65-8 methyl 5-(4-benzyloxyphenyl)-4-N-(t-butoxycarbonyl)amino-3-oxopentanoate 
• 129081-63-6 methyl 5-phenyl-4-(9-fluorenylmethoxycarbonyl)amino-3-oxopentanoate 
• 101669-73-2 methyl (S)-4-[(tert-butoxycarbonyl)amino]-3-oxo-5-phenylpentanoate 
• 119038-15-2 Boc-Tyr(Bzl)-Nle-Ψ(NH-CO)-Gly-OMe 

Relevant articles and documents

COUMARIN-MODIFIED ANDROGENS FOR THE TREATMENT OF PROSTATE CANCER

Provided are androstane and dihydrotestosterone compounds functionalized with carbocyclic groups or heterocyclic groups that may be saturated or unsaturated. The compounds may be used in methods of inhibiting cell growth of malignant cells and/or hyperplastic cells and/or treating individuals having diseases associated with malignant cell growth (e.g., cancer, such as, for example, prostate cancer) and/or hyperplastic cell growth and/or molecular imaging of malignant cells and/or hyperplastic cells and/or inducing degradation of a target protein. Also provided are compositions.

Formal synthesis of (+)-lactacystin from l-serine

A formal, stereocontrolled synthesis of lactacystin has been completed from t-Bu-O-l-serine, providing the key intermediate 13, also useful for the generation of a range of C-9 analogues.

Preparation method for polyfluoromethylpyrazole compound, and intermediate of compound and preparation method thereof

The invention discloses a preparation method for a polyfluoromethylpyrazole compound, and an intermediate of the compound and a preparation method thereof. The invention provides a preparation method for a compound 1 as defined in the specification. The preparation method comprises a step of subjecting a compound 2 as defined in the specification and methylhydrazine to a ring-closure reaction in an organic solvent so as to obtain the compound 1, wherein R is a C1-4 alkyl group, R is a methyl or ethyl group and x is 2 or 3. The preparation method provided by the invention uses cheap and easily available raw materials and is mild in reaction conditions, safe to operate, environment friendly, low in production cost, high in reaction conversion rate, low in the content of isomer in by-products, high in reaction yield and product purity and suitable for industrial production.

MULTISTAGE PROCESS FOR PREPARING ALKALI METAL SALTS OF SPECIFIC 4-HYDROXY-2-OXO-2,5-DIHYDROFURAN-3-CARBOXYLIC ESTERS

The present invention relates to a multi-stage method for preparing alkali metal salts of specific 4-hydroxy-2-oxo-2,5-dihydrofuran-3-carboxylic esters of the formula (I), in which M and R1 are as defined in the description, which proceeds from malonic ester and does not require isolation of intermediates.

Pd-catalyzed decarboxylative cross-couplings of potassium malonate monoesters with aryl halides

An efficient catalytic protocol for Pd-catalyzed decarboxylative cross-coupling of potassium malonate monoesters and derivatives with aryl bromides and chlorides are described. Because of its broad applicability, this new catalytic system provides an alternative method for the preparation of diverse aryl acetic acids and derivatives.

Synthesis of α-Aryl nitriles through palladium-catalyzed decarboxylative coupling of cyanoacetate salts with aryl halides and triflates

Worth its salt: The palladium-catalyzed decarboxylative coupling of the cyanoacetate salt as well as its mono- and disubstituted derivatives with aryl chlorides, bromides, and triflates is described (see scheme). This reaction is potentially useful for the preparation of a diverse array of α-aryl nitriles and has good functional group tolerance. S-Phos=2-(2,6- dimethoxybiphenyl)dicyclohexylphosphine), Xant-Phos=4,5-bis(diphenylphosphino)- 9,9-dimethylxanthene. Copyright

Preparation of cilazapril intermediates

The present application relates to cilazapril intermediates and processes for the preparation of cilazapril intermediates, including (S)-6,11-dioxo-1,2,3,4,6,11-hexahydro-pyridazino[1,2-b]naphthalazine-1-carboxylic acid and its salts.

Discovery and structure-activity relationships of trisubstituted pyrimidines/pyridines as novel calcium-sensing receptor antagonists

The trisubstituted pyrimidine 1 was identified through high-throughput screening as a novel calcium-sensing receptor (CaSR) antagonist. Small molecule CaSR antagonists and/or negative allosteric modulators have the potential to act as an anabolic agent for the treatment of osteoporosis. The investigation of structure-activity relationships around 1 resulted in the identification of 18c and 18d, which showed efficacy at promoting PTH release in vivo and exhibited improved potency and solubility over the original lead 1.

TRISUBSTITUTED HETEROAROMATIC COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS

Trisubstituted heteroaromatic compounds having the structure Formula (I) are provided, wherein X is C or N; A and B are each independently CH or N, with the proviso that A and B cannot both be CH; R is Ar-L-; R is hydrogen or alkyl; or R and R can be joined together to form a 4- to 7-membered cycloheteroalkyl ring; R to R, Ar and L are as defined herein. A method for using these compounds to treat diseases associated with abnormal bone or mineral homeostasis is also provided.

Process for preparing potassium monoethyl malonate

A process for preparing potassium monoethyl malonate by selective saponification of malonic acid diethyl ester with potassium hydroxide, in which the potassium hydroxide is added to the malonic acid diethyl ester, malonic acid diethyl ester and potassium hydroxide are used in a molar ratio of at least 1.5 and the potassium hydroxide is effectively distributed into the malonic acid diethyl ester.